Brief: United Therapeutics Corporation Announces FDA Filing Acceptance Of New Drug Application For Ralinepag
24/08/2026 12:10
BRIEF-United Therapeutics Corporation Announces FDA Filing Acceptance Of New Drug Application For Ralinepag Aug 24 (Reuters) - United Therapeutics Corporation UTHR.O:
UNITED THERAPEUTICS CORPORATION ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR RALINEPAG TO TREAT PULMONARY ARTERIAL HYPERTENSION
UNITED THERAPEUTICS CORPORATION - FDA SETS PDUFA TARGET ACTION DATE FOR RALINEPAG ON JUNE 24, 2027
UNITED THERAPEUTICS CORPORATION: RALINEPAG HAS NOT BEEN APPROVED FOR USE IN ANY INDICATION BY FDA AND REMAINS INVESTIGATIONAL FOR PAH
Source text: ID:nBwbGJDyna
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug